Yeah, so this was on the Phase II evobrutinib study. Approximately 170 patients provided samples for serum neurofilament light chain measurements. This was a study versus placebo or low dose evobrutinib and high dose evobrutinib. We had seen earlier that high dose evobrutinib showed a significant reduction of serum neurofilament light levels, I think as early as six weeks after starting the treatment...
Yeah, so this was on the Phase II evobrutinib study. Approximately 170 patients provided samples for serum neurofilament light chain measurements. This was a study versus placebo or low dose evobrutinib and high dose evobrutinib. We had seen earlier that high dose evobrutinib showed a significant reduction of serum neurofilament light levels, I think as early as six weeks after starting the treatment. This work here was now looking at prognostic value of baseline serum NfL levels on new T2 lesions, gadolinium lesions, and relapses, and we saw a clear signal that patients with higher NfL at baseline also showed more gadolinium activity, more new T2 lesion activity, and more relapses over the six months study later on. And we also saw that high dose evobrutinib significantly reduced these endpoints independent of having high or low NfL levels at baseline.